X4 Pharmaceuticals, Inc. - Common Stock – Quartals-Cashflow (NASDAQ:XFOR) | MetaTrader

Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Gesamtvermögen 146.45 M130.01 M105.17 M163.56 M290.46 M270.28 M Gesamtverbindlichkeiten 124.3 M107.07 M101.2 M101.94 M104.17 M101.83 M Gesamtkapital 22.15 M22.94 M3.97 M61.62 M186.29 M168.45 M Gesamtverbindlichkeiten und Eigenkapital 146.45 M130.01 M105.17 M163.56 M290.46 M270.28 M Gesamtverschuldung —————— Nettoverschuldung ——————

Nachrichten

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

X4 Pharmaceuticals erhält EU-Zulassung für Medikament gegen WHIM-Syndrom

Stifel bekräftigt Kaufempfehlung für X4 Pharmaceuticals nach Studienfortschritten

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

EMA-Ausschuss empfiehlt Zulassung von Mavorixafor für seltenes WHIM-Syndrom